Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party

Sung Hoon Jung, Se Ryeon Lee, Deok Hwan Yang, Seok Lee, Jae Ho Yoon, Hyewon Lee, Soo Mee Bang, Youngil Koh, Silvia Park, Dae Sik Kim, Ho Young Yhim, Sung Hyun Kim, Ji Hyun Lee, Sang Kyun Sohn, Ik Chan Song, Hong ghi Lee, Jung Won Cheong, Yunsuk Choi, Ho Jin Shin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Blinatumomab, a bispecific T cell-engaging antibody, has demonstrated efficacy for relapsed or refractory acute lymphoblastic leukemia (ALL). In this study, we evaluated the efficacy and toxicity of blinatumomab in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL. A total of 50 patients received blinatumomab treatment between June 2016 and August 2017 in Korea. The median number of prior therapy was one (range, 1–4). Among the 49 evaluable patients, 22 (44.9%) achieved complete response (CR) or CR with incomplete blood count recovery, and 16 of whom subsequently underwent allogenic stem cell transplantation. Although no statistically significant differences were observed, patients with extramedullary disease and poor performance status had lower responses to blinatumomab treatment. In addition, the use of high-dose dexamethasone prior to blinatumomab treatment did not affect the response to blinatumomab. The median event-free survival and overall survival of the responders were 7.5 and 8.1 months, respectively. For non-hematologic toxicities, the most common toxicity was infection. The incidences of severe cytokine release syndrome and neurologic toxicity each was 4%. In conclusion, blinatumomab was an effective and tolerable therapy in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL.

Original languageEnglish
JournalAnnals of Hematology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Keywords

  • Acute lymphoblastic leukemia
  • Blinatumomab
  • Predictor

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party'. Together they form a unique fingerprint.

  • Cite this

    Jung, S. H., Lee, S. R., Yang, D. H., Lee, S., Yoon, J. H., Lee, H., Bang, S. M., Koh, Y., Park, S., Kim, D. S., Yhim, H. Y., Kim, S. H., Lee, J. H., Sohn, S. K., Song, I. C., Lee, H. G., Cheong, J. W., Choi, Y., & Shin, H. J. (Accepted/In press). Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. Annals of Hematology. https://doi.org/10.1007/s00277-018-3495-2